Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease

PURPOSE: There is no universal consensus on second-line agents for the treatment of moderate/severe to sight-threatening thyroid eye disease (TED) to maintain remission after first-line intravenous methylprednisolone (IVMP). This study investigates the efficacy and safety of mycophenolate mofetil (M...

Descripción completa

Detalles Bibliográficos
Autores principales: Quah Qin Xian, Nicole, Alnahrawy, Ahmed, Akshikar, Rashmi, Lee, Vickie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121682/
https://www.ncbi.nlm.nih.gov/pubmed/34007144
http://dx.doi.org/10.2147/OPTH.S305717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121682/
https://www.ncbi.nlm.nih.gov/pubmed/34007144
http://dx.doi.org/10.2147/OPTH.S305717

Ejemplares similares